^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Cancer

    Related cancers:
    22h
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    22h
    SKB571-II-02: A Phase II Study of SKB571 in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=295, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | N=190 --> 295
    Enrollment change
    23h
    DESTINY-Lung05: A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    1d
    VALO-001: START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Valo Therapeutics Oy | Active, not recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Oct 2026 --> Apr 2027
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • MAGEA3 (MAGE Family Member A3)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1
    1d
    Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC (clinicaltrials.gov)
    P2, N=14, Completed, Case Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib)
    1d
    Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative (clinicaltrials.gov)
    P1/2, N=108, Completed, Sunshine Lake Pharma Co., Ltd. | Active, not recruiting --> Completed | N=158 --> 108
    Trial completion • Enrollment change
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation
    |
    gefitinib • ningetinib (CT053PTSA)
    1d
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    1d
    A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment (clinicaltrials.gov)
    P=N/A, N=200, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK rearrangement
    |
    Lorbrena (lorlatinib)
    1d
    DOTATOC PET/CT for Imaging NET Patients (clinicaltrials.gov)
    P=N/A, N=800, Active, not recruiting, British Columbia Cancer Agency | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    1d
    PLuS2: Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations (clinicaltrials.gov)
    P=N/A, N=1826, Active, not recruiting, University of Florida
    New trial • Real-world evidence
    1d
    A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=46, Not yet recruiting, Health Hope Pharma
    New P1 trial
    |
    paclitaxel
    1d
    CPG-02-101: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=94, Completed, Compugen Ltd | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • COM701 • COM902